ArticleBMC neurology2026
Towards personalized vaccine repurposing for Alzheimer's prevention: genotype-specific protective association of the shingles vaccine with odds of Alzheimer's disease in participants of two large cohort studies.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOur earlier study found that adult vaccination against shingles (herpes zoster infection caused by the reactivation of the varicella-zoster virus) was associated with significantly reduced risk of Alzheimer's disease (AD) later in life. Here, we investigated genotype-specific associations between the shingles vaccine and the odds of AD using data from the Health and Retirement Study (HRS) and the UK Biobank (UKB).
methodsThis prospective case–control study included genotyped participants from the HRS (N = 9,188) and UKB (N = 66,748) cohorts, who survived beyond age 75. Multivariable logistic regression models were applied to assess associations between vaccination against shingles and later onset of AD. Vaccination status was defined as having received at least one live attenuated herpes zoster vaccine between ages 65 and 75. The outcome was AD onset after age 75. The analysis was stratified by carrier status of minor allele (A) of the SNP rs6859, a risk factor for AD located in NECTIN2 gene, which is involved in vulnerability to viral infections. Observed covariates included education, smoking, APOE4 allele counts, and (when not stratified) race and sex.
resultsReceiving the shingles vaccine between ages 65 and 75 was associated with significantly lower odds of AD onset later in life (OR = 0.55, p-value = 0.021) in an unstratified HRS sample. After stratification, the AD-protective association became stronger in carriers of the rs6859 (A) allele (OR = 0.43, p-value = 0.016), especially in females (OR = 0.28, p-value = 0.018). In non-carriers of (A) allele, the association between the shingles vaccine and AD became non-significant. Similar associations were observed in the UKB (OR = 0.53, p-value < 0.001 in an unstratified sample; OR = 0.51, p-value = 0.001 in rs6859 (A) carriers; and non-significant results in non-carriers).
conclusionsVaccination against shingles received between ages 65 and 75 is associated with significantly lower odds of AD onset later in life in both HRS and UKB cohorts, especially in female carriers of the rs6859 (A) allele, a genetic risk factor for AD in NECTIN2 gene. Our results support personalized repurposing of the shingles vaccine for AD prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.